tooluniverse-drug-mechanism-research
# ClaudeWave Item Description The tooluniverse-drug-mechanism-research skill traces how drugs work by mapping the chain from primary molecular target through downstream signaling pathways to organ-level effects and clinical outcomes. It integrates DrugBank, ChEMBL, KEGG, Reactome, and STRING databases to answer questions about drug mechanisms of action, off-target effects, and mechanism-based combination therapy design, making it essential for mechanistic drug analysis and writing pharmacology sections in research reports.
git clone --depth 1 https://github.com/mims-harvard/ToolUniverse /tmp/tooluniverse-drug-mechanism-research && cp -r /tmp/tooluniverse-drug-mechanism-research/plugin/skills/tooluniverse-drug-mechanism-research ~/.claude/skills/tooluniverse-drug-mechanism-researchSKILL.md
# Drug Mechanism of Action Investigation
## Investigation Philosophy
Drug mechanism research follows one core question chain:
**Target -> Downstream Effect -> Pathway -> Organ Effect -> Clinical Outcome**
Start with the drug's primary target. What receptor, enzyme, or transporter does it bind? Then trace forward: what does inhibiting/activating that target do immediately? What pathway is disrupted? What organ-level change results? What does the patient experience?
The LLM already knows drug pharmacology. This skill teaches HOW TO INVESTIGATE using available tools, not what mechanisms exist.
## When to Use
- "What is the mechanism of action of [drug]?"
- "What are the molecular targets of [drug]?"
- "Which pathways are affected by [drug]?"
- "What pharmacogenomic interactions exist for [drug]?"
- "What are the off-targets of [drug]?"
- "Compare mechanisms of [drug A] vs [drug B]"
## NOT for (use other skills)
- Drug safety/adverse events profiling -> `tooluniverse-adverse-event-detection`
- Drug repurposing/new indications -> `tooluniverse-drug-repurposing`
- Target druggability assessment -> `tooluniverse-drug-target-validation`
- Network pharmacology/polypharmacology -> `tooluniverse-network-pharmacology`
- CPIC dosing guidelines specifically -> `tooluniverse-pharmacogenomics`
---
## Step 1: Resolve the Drug
Before investigating mechanism, resolve the drug name to a canonical identifier. You need a ChEMBL ID for most downstream queries.
```python
# Resolve drug name to ChEMBL ID
result = tu.tools.OpenTargets_get_drug_id_description_by_name(drugName="metformin")
# Alternative: OpenTargets_get_drug_chembId_by_generic_name(drugName="metformin")
# Get PharmGKB ID (needed for PGx queries)
result = tu.tools.PharmGKB_search_drugs(query="metformin")
```
**Fallback**: If OpenTargets returns no hits, try `PharmGKB_search_drugs` or `ChEMBL_get_drug` with a known ChEMBL ID.
---
## Step 2: Identify the Primary Target
The first question: what does this drug bind to, and what does it do to that target?
Two complementary sources give you this:
```python
# OpenTargets: quick summary of MOA with target gene symbols
moa = tu.tools.OpenTargets_get_drug_mechanisms_of_action_by_chemblId(chemblId="CHEMBL1431")
for row in moa["data"]["drug"]["mechanismsOfAction"]["rows"]:
print(f"{row['mechanismOfAction']} ({row['actionType']}) -> {row['targetName']}")
for t in row.get("targets", []):
print(f" Target gene: {t['approvedSymbol']} ({t['id']})")
# ChEMBL: detailed MOA with literature references and direct_interaction flag
mechs = tu.tools.ChEMBL_get_drug_mechanisms(drug_chembl_id__exact="CHEMBL1431")
for m in mechs["data"]["mechanisms"]:
print(f"MOA: {m['mechanism_of_action']}, Direct: {m['direct_interaction']}")
print(f" Refs: {[r['ref_id'] for r in m.get('mechanism_refs', [])]}")
```
**Key fields to extract**: action_type (INHIBITOR, AGONIST, ANTAGONIST, etc.), target gene symbol, direct_interaction (boolean), and literature references.
**Known issue**: `OpenTargets_get_associated_targets_by_drug_chemblId` may fail (GraphQL schema change). Extract targets from the MOA results instead.
---
## Step 3: Assess Off-Target Effects
Most drugs bind more than one target at clinical concentrations. After identifying the primary target, ask: what other proteins does this drug interact with? Off-target binding explains many side effects and drug interactions.
```python
# ChEMBL bioactivity data shows binding affinity across targets
activities = tu.tools.ChEMBL_get_target_activities(target_chembl_id__exact="CHEMBL2364")
# STRING interaction partners reveal the target's protein network
partners = tu.tools.STRING_get_interaction_partners(identifiers="PRKAA1", species=9606)
```
**Reasoning strategy**: If ChEMBL MOA lists multiple targets, compare their action types. Same action type across related targets suggests on-pathway polypharmacology. Different action types suggest true off-target effects. The binding affinity (IC50/Ki from bioactivity data) tells you which targets matter at clinical doses -- nanomolar affinity is primary, micromolar is likely off-target.
---
## Step 4: Map to Pathway Context
A drug target does not work in isolation. Map it to its pathway to understand the breadth of effect.
**Key question**: Is the target upstream (affects many downstream genes, broader effects, more side effects) or downstream (narrow, specific effect)?
```python
# KEGG: find gene ID, then get pathways
genes = tu.tools.kegg_find_genes(keyword="PRKAA1", organism="hsa")
pathways = tu.tools.KEGG_get_gene_pathways(gene_id="hsa:5562")
# Reactome: map protein to pathways (needs UniProt ID)
reactome = tu.tools.Reactome_map_uniprot_to_pathways(uniprot_id="Q13131")
# WikiPathways: search by gene symbol
wp = tu.tools.WikiPathways_find_pathways_by_gene(gene="PRKAA1")
# STRING: functional annotations (GO terms, pathway memberships)
annot = tu.tools.STRING_get_functional_annotations(identifiers="PRKAA1", species=9606)
```
**For multi-target drugs**, run pathway enrichment to find convergent pathways:
```python
# Reactome enrichment (space-separated gene list, NOT array)
enrichment = tu.tools.ReactomeAnalysis_pathway_enrichment(identifiers="PRKAA1 PRKAA2 PRKAB1")
# STRING enrichment
enrichment = tu.tools.STRING_functional_enrichment(identifiers="PRKAA1 PRKAA2", species=9606)
```
**Reasoning strategy**: If multiple drug targets converge on the same pathway, that pathway is the drug's true mechanism. If targets are in different pathways, the drug has genuinely multi-pathway effects -- report each separately.
---
## Step 5: Get the Regulatory View (DailyMed)
Drug labels describe WHAT the drug does. This is the FDA-approved mechanism narrative.
DailyMed requires a two-step process: search for the drug to get a `setid`, then parse specific label sections.
```python
# Step 1: Get setid
spls = tu.tools.DailyMed_search_spls(drug_name="metformin")
setid = spls["data"][0]["setid"]
# StInstall and configure ToolUniverse for any use case — MCP server (chat-based), CLI (command line with 9 subcommands), or Python SDK (Coding API with 3 calling patterns). Covers uv/uvx setup, MCP configuration for 12+ AI clients (Cursor, Claude Desktop, Windsurf, VS Code, Codex, Gemini CLI, Trae, Cline, etc.), full CLI reference (tu list/grep/find/info/run/test/status/build/serve), Coding API quickstart, agentic tools, code executor, API key walkthrough, skill installation, and upgrading. Use when user asks how to set up ToolUniverse, which access mode to use (MCP vs CLI vs SDK), configuring MCP servers, using the CLI, troubleshooting installation, upgrading, or mentions installing ToolUniverse or setting up scientific tools. Also triggers for "how do I use ToolUniverse", "what's the best way to access tools", "command line", "tu command", "coding API", "tu build".
Systematic ACMG/AMP germline variant classification with all 28 criteria (PVS1, PS1-4, PM1-6, PP1-5, BA1, BS1-4, BP1-7) for clinical significance. Produces 5-tier verdict (Pathogenic / Likely Pathogenic / VUS / Likely Benign / Benign) with cited evidence per criterion. Use for variant interpretation, VUS resolution, and pathogenicity assessment. Combines ClinVar, gnomAD, computational predictors, and gene-mechanism context.
Comprehensive ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiling for drug candidates. Integrates ADMET-AI predictions, SwissADME drug-likeness, PubChemTox experimental toxicity, ChEMBL clinical data, Lipinski rule-of-five, and CYP interaction data. Use for drug-likeness assessment, BBB penetration, bioavailability, hepatotoxicity prediction, ADME/PK profiling, or screening compound libraries before lab testing.
Detect and analyze adverse drug event signals using FDA FAERS reports, drug labels, and disproportionality statistics (PRR, ROR, IC). Generates quantitative safety signal scores (0-100) with evidence grading. Use for post-market surveillance, pharmacovigilance, drug safety assessment, regulatory submissions, and detecting rare AE signals not visible in clinical trials.
Map environmental and industrial chemicals to adverse outcome pathways (AOPs) — molecular initiating event to organ-level toxicity. Uses AOPWiki, GHS classification, IARC carcinogen status, and LD50 data. Use for environmental/industrial chemical risk assessment, regulatory-grade hazard characterization, and AOP stressor mapping. Distinct from drug-safety analysis (use tooluniverse-pharmacovigilance for drugs).
Aging biology, cellular senescence, and longevity research. Covers senescence markers (p16/CDKN2A, SASP, SA-beta-gal), aging hallmarks, senolytic drug discovery (dasatinib+quercetin, fisetin, navitoclax), epigenetic clocks, telomere biology, and longevity GWAS. Use for senescence-pathway analysis, age-related disease genetics, senolytic-target discovery, and centenarian-genetics queries. Distinguishes correlative vs causal evidence (knockout, intervention).
Therapeutic antibody engineering and optimization, lead-to-clinical-candidate. Covers sequence humanization (germline alignment, framework retention), affinity maturation, developability (aggregation, stability, PTMs), structure modeling (AlphaFold/PDB CDR analysis), immunogenicity prediction, and manufacturing feasibility. Use for biologic-drug optimization, mAb design review, biosimilar engineering, and clinical-precedent comparison.
Discover novel small-molecule binders for protein targets using structure-based and ligand-based screening. Covers druggability assessment, known-ligand mining (ChEMBL, BindingDB), similarity expansion, ADMET filtering, and synthesis feasibility. Use for hit identification, virtual screening, target-to-compounds workflows, and lead-finding before commit-to-medchem.